Home Healthcare Pharmaceuticals Antiviral Drugs Market

Antiviral Drugs Market Size, Share & Trends Analysis Report By Drug Class (DNA Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Protease Inhibitors, Neuraminidase Inhibitors, RNAi Antisense Therapeutics, Capsid Inhibitors, Others), By Application (HIV, Hepatitis, Herpes, Influenza, Respiratory Syncytial Virus, Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: August 21, 2026 | Author: Debashree Bora | Format:
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Antiviral Drugs Market, By Drug Class 2022-2034 (USD MILLION/ Units)
    1. DNA Polymerase Inhibitors
    2. Reverse Transcriptase Inhibitors
    3. Protease Inhibitors
    4. Neuraminidase Inhibitors
    5. RNAi Antisense Therapeutics
    6. Capsid Inhibitors
    7. Others
  2. Antiviral Drugs Market, By Application 2022-2034 (USD MILLION/ Units)
    1. HIV
    2. Hepatitis
    3. Herpes
    4. Influenza
    5. Respiratory Syncytial Virus
    6. Others
  3. Antiviral Drugs Market, By Distribution Channel 2022-2034 (USD MILLION/ Units)
    1. Hospital Pharmacy
    2. Retail Pharmacy
    3. Online Pharmacy
  4. Regional Antiviral Drugs Market
    1. North America
      1. North America Antiviral Drugs Market By Drug Class 2022-2034 (USD MILLION/ Units)
        1. DNA Polymerase Inhibitors
        2. Reverse Transcriptase Inhibitors
        3. Protease Inhibitors
        4. Neuraminidase Inhibitors
        5. RNAi Antisense Therapeutics
        6. Capsid Inhibitors
        7. Others
      2. North America Antiviral Drugs Market By Application 2022-2034 (USD MILLION/ Units)
        1. HIV
        2. Hepatitis
        3. Herpes
        4. Influenza
        5. Respiratory Syncytial Virus
        6. Others
      3. North America Antiviral Drugs Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacy
        2. Retail Pharmacy
        3. Online Pharmacy
      4. U.S.
        1. DNA Polymerase Inhibitors
        2. Reverse Transcriptase Inhibitors
        3. Protease Inhibitors
        4. Neuraminidase Inhibitors
        5. RNAi Antisense Therapeutics
        6. Capsid Inhibitors
        7. Others
        8. HIV
        9. Hepatitis
        10. Herpes
        11. Influenza
        12. Respiratory Syncytial Virus
        13. Others
        14. Hospital Pharmacy
        15. Retail Pharmacy
        16. Online Pharmacy
      5. Canada
        1. DNA Polymerase Inhibitors
        2. Reverse Transcriptase Inhibitors
        3. Protease Inhibitors
        4. Neuraminidase Inhibitors
        5. RNAi Antisense Therapeutics
        6. Capsid Inhibitors
        7. Others
        8. HIV
        9. Hepatitis
        10. Herpes
        11. Influenza
        12. Respiratory Syncytial Virus
        13. Others
        14. Hospital Pharmacy
        15. Retail Pharmacy
        16. Online Pharmacy
    2. Europe
      1. Europe Antiviral Drugs Market By Drug Class 2022-2034 (USD MILLION/ Units)
        1. DNA Polymerase Inhibitors
        2. Reverse Transcriptase Inhibitors
        3. Protease Inhibitors
        4. Neuraminidase Inhibitors
        5. RNAi Antisense Therapeutics
        6. Capsid Inhibitors
        7. Others
      2. Europe Antiviral Drugs Market By Application 2022-2034 (USD MILLION/ Units)
        1. HIV
        2. Hepatitis
        3. Herpes
        4. Influenza
        5. Respiratory Syncytial Virus
        6. Others
      3. Europe Antiviral Drugs Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacy
        2. Retail Pharmacy
        3. Online Pharmacy
      4. U.K.
        1. DNA Polymerase Inhibitors
        2. Reverse Transcriptase Inhibitors
        3. Protease Inhibitors
        4. Neuraminidase Inhibitors
        5. RNAi Antisense Therapeutics
        6. Capsid Inhibitors
        7. Others
        8. HIV
        9. Hepatitis
        10. Herpes
        11. Influenza
        12. Respiratory Syncytial Virus
        13. Others
        14. Hospital Pharmacy
        15. Retail Pharmacy
        16. Online Pharmacy
      5. Germany
        1. DNA Polymerase Inhibitors
        2. Reverse Transcriptase Inhibitors
        3. Protease Inhibitors
        4. Neuraminidase Inhibitors
        5. RNAi Antisense Therapeutics
        6. Capsid Inhibitors
        7. Others
        8. HIV
        9. Hepatitis
        10. Herpes
        11. Influenza
        12. Respiratory Syncytial Virus
        13. Others
        14. Hospital Pharmacy
        15. Retail Pharmacy
        16. Online Pharmacy
      6. France
        1. DNA Polymerase Inhibitors
        2. Reverse Transcriptase Inhibitors
        3. Protease Inhibitors
        4. Neuraminidase Inhibitors
        5. RNAi Antisense Therapeutics
        6. Capsid Inhibitors
        7. Others
        8. HIV
        9. Hepatitis
        10. Herpes
        11. Influenza
        12. Respiratory Syncytial Virus
        13. Others
        14. Hospital Pharmacy
        15. Retail Pharmacy
        16. Online Pharmacy
      7. Spain
        1. DNA Polymerase Inhibitors
        2. Reverse Transcriptase Inhibitors
        3. Protease Inhibitors
        4. Neuraminidase Inhibitors
        5. RNAi Antisense Therapeutics
        6. Capsid Inhibitors
        7. Others
        8. HIV
        9. Hepatitis
        10. Herpes
        11. Influenza
        12. Respiratory Syncytial Virus
        13. Others
        14. Hospital Pharmacy
        15. Retail Pharmacy
        16. Online Pharmacy
      8. Italy
        1. DNA Polymerase Inhibitors
        2. Reverse Transcriptase Inhibitors
        3. Protease Inhibitors
        4. Neuraminidase Inhibitors
        5. RNAi Antisense Therapeutics
        6. Capsid Inhibitors
        7. Others
        8. HIV
        9. Hepatitis
        10. Herpes
        11. Influenza
        12. Respiratory Syncytial Virus
        13. Others
        14. Hospital Pharmacy
        15. Retail Pharmacy
        16. Online Pharmacy
      9. Russia
        1. DNA Polymerase Inhibitors
        2. Reverse Transcriptase Inhibitors
        3. Protease Inhibitors
        4. Neuraminidase Inhibitors
        5. RNAi Antisense Therapeutics
        6. Capsid Inhibitors
        7. Others
        8. HIV
        9. Hepatitis
        10. Herpes
        11. Influenza
        12. Respiratory Syncytial Virus
        13. Others
        14. Hospital Pharmacy
        15. Retail Pharmacy
        16. Online Pharmacy
      10. Nordic
        1. DNA Polymerase Inhibitors
        2. Reverse Transcriptase Inhibitors
        3. Protease Inhibitors
        4. Neuraminidase Inhibitors
        5. RNAi Antisense Therapeutics
        6. Capsid Inhibitors
        7. Others
        8. HIV
        9. Hepatitis
        10. Herpes
        11. Influenza
        12. Respiratory Syncytial Virus
        13. Others
        14. Hospital Pharmacy
        15. Retail Pharmacy
        16. Online Pharmacy
      11. Benelux
        1. DNA Polymerase Inhibitors
        2. Reverse Transcriptase Inhibitors
        3. Protease Inhibitors
        4. Neuraminidase Inhibitors
        5. RNAi Antisense Therapeutics
        6. Capsid Inhibitors
        7. Others
        8. HIV
        9. Hepatitis
        10. Herpes
        11. Influenza
        12. Respiratory Syncytial Virus
        13. Others
        14. Hospital Pharmacy
        15. Retail Pharmacy
        16. Online Pharmacy
      12. Rest of Europe
        1. DNA Polymerase Inhibitors
        2. Reverse Transcriptase Inhibitors
        3. Protease Inhibitors
        4. Neuraminidase Inhibitors
        5. RNAi Antisense Therapeutics
        6. Capsid Inhibitors
        7. Others
        8. HIV
        9. Hepatitis
        10. Herpes
        11. Influenza
        12. Respiratory Syncytial Virus
        13. Others
        14. Hospital Pharmacy
        15. Retail Pharmacy
        16. Online Pharmacy
    3. APAC
      1. APAC Antiviral Drugs Market By Drug Class 2022-2034 (USD MILLION/ Units)
        1. DNA Polymerase Inhibitors
        2. Reverse Transcriptase Inhibitors
        3. Protease Inhibitors
        4. Neuraminidase Inhibitors
        5. RNAi Antisense Therapeutics
        6. Capsid Inhibitors
        7. Others
      2. APAC Antiviral Drugs Market By Application 2022-2034 (USD MILLION/ Units)
        1. HIV
        2. Hepatitis
        3. Herpes
        4. Influenza
        5. Respiratory Syncytial Virus
        6. Others
      3. APAC Antiviral Drugs Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacy
        2. Retail Pharmacy
        3. Online Pharmacy
      4. China
        1. DNA Polymerase Inhibitors
        2. Reverse Transcriptase Inhibitors
        3. Protease Inhibitors
        4. Neuraminidase Inhibitors
        5. RNAi Antisense Therapeutics
        6. Capsid Inhibitors
        7. Others
        8. HIV
        9. Hepatitis
        10. Herpes
        11. Influenza
        12. Respiratory Syncytial Virus
        13. Others
        14. Hospital Pharmacy
        15. Retail Pharmacy
        16. Online Pharmacy
      5. Korea
        1. DNA Polymerase Inhibitors
        2. Reverse Transcriptase Inhibitors
        3. Protease Inhibitors
        4. Neuraminidase Inhibitors
        5. RNAi Antisense Therapeutics
        6. Capsid Inhibitors
        7. Others
        8. HIV
        9. Hepatitis
        10. Herpes
        11. Influenza
        12. Respiratory Syncytial Virus
        13. Others
        14. Hospital Pharmacy
        15. Retail Pharmacy
        16. Online Pharmacy
      6. Japan
        1. DNA Polymerase Inhibitors
        2. Reverse Transcriptase Inhibitors
        3. Protease Inhibitors
        4. Neuraminidase Inhibitors
        5. RNAi Antisense Therapeutics
        6. Capsid Inhibitors
        7. Others
        8. HIV
        9. Hepatitis
        10. Herpes
        11. Influenza
        12. Respiratory Syncytial Virus
        13. Others
        14. Hospital Pharmacy
        15. Retail Pharmacy
        16. Online Pharmacy
      7. India
        1. DNA Polymerase Inhibitors
        2. Reverse Transcriptase Inhibitors
        3. Protease Inhibitors
        4. Neuraminidase Inhibitors
        5. RNAi Antisense Therapeutics
        6. Capsid Inhibitors
        7. Others
        8. HIV
        9. Hepatitis
        10. Herpes
        11. Influenza
        12. Respiratory Syncytial Virus
        13. Others
        14. Hospital Pharmacy
        15. Retail Pharmacy
        16. Online Pharmacy
      8. Australia
        1. DNA Polymerase Inhibitors
        2. Reverse Transcriptase Inhibitors
        3. Protease Inhibitors
        4. Neuraminidase Inhibitors
        5. RNAi Antisense Therapeutics
        6. Capsid Inhibitors
        7. Others
        8. HIV
        9. Hepatitis
        10. Herpes
        11. Influenza
        12. Respiratory Syncytial Virus
        13. Others
        14. Hospital Pharmacy
        15. Retail Pharmacy
        16. Online Pharmacy
      9. Taiwan
        1. DNA Polymerase Inhibitors
        2. Reverse Transcriptase Inhibitors
        3. Protease Inhibitors
        4. Neuraminidase Inhibitors
        5. RNAi Antisense Therapeutics
        6. Capsid Inhibitors
        7. Others
        8. HIV
        9. Hepatitis
        10. Herpes
        11. Influenza
        12. Respiratory Syncytial Virus
        13. Others
        14. Hospital Pharmacy
        15. Retail Pharmacy
        16. Online Pharmacy
      10. South East Asia
        1. DNA Polymerase Inhibitors
        2. Reverse Transcriptase Inhibitors
        3. Protease Inhibitors
        4. Neuraminidase Inhibitors
        5. RNAi Antisense Therapeutics
        6. Capsid Inhibitors
        7. Others
        8. HIV
        9. Hepatitis
        10. Herpes
        11. Influenza
        12. Respiratory Syncytial Virus
        13. Others
        14. Hospital Pharmacy
        15. Retail Pharmacy
        16. Online Pharmacy
      11. Rest of Asia-Pacific
        1. DNA Polymerase Inhibitors
        2. Reverse Transcriptase Inhibitors
        3. Protease Inhibitors
        4. Neuraminidase Inhibitors
        5. RNAi Antisense Therapeutics
        6. Capsid Inhibitors
        7. Others
        8. HIV
        9. Hepatitis
        10. Herpes
        11. Influenza
        12. Respiratory Syncytial Virus
        13. Others
        14. Hospital Pharmacy
        15. Retail Pharmacy
        16. Online Pharmacy
    4. Middle East and Africa
      1. Middle East and Africa Antiviral Drugs Market By Drug Class 2022-2034 (USD MILLION/ Units)
        1. DNA Polymerase Inhibitors
        2. Reverse Transcriptase Inhibitors
        3. Protease Inhibitors
        4. Neuraminidase Inhibitors
        5. RNAi Antisense Therapeutics
        6. Capsid Inhibitors
        7. Others
      2. Middle East and Africa Antiviral Drugs Market By Application 2022-2034 (USD MILLION/ Units)
        1. HIV
        2. Hepatitis
        3. Herpes
        4. Influenza
        5. Respiratory Syncytial Virus
        6. Others
      3. Middle East and Africa Antiviral Drugs Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacy
        2. Retail Pharmacy
        3. Online Pharmacy
      4. UAE
        1. DNA Polymerase Inhibitors
        2. Reverse Transcriptase Inhibitors
        3. Protease Inhibitors
        4. Neuraminidase Inhibitors
        5. RNAi Antisense Therapeutics
        6. Capsid Inhibitors
        7. Others
        8. HIV
        9. Hepatitis
        10. Herpes
        11. Influenza
        12. Respiratory Syncytial Virus
        13. Others
        14. Hospital Pharmacy
        15. Retail Pharmacy
        16. Online Pharmacy
      5. Turkey
        1. DNA Polymerase Inhibitors
        2. Reverse Transcriptase Inhibitors
        3. Protease Inhibitors
        4. Neuraminidase Inhibitors
        5. RNAi Antisense Therapeutics
        6. Capsid Inhibitors
        7. Others
        8. HIV
        9. Hepatitis
        10. Herpes
        11. Influenza
        12. Respiratory Syncytial Virus
        13. Others
        14. Hospital Pharmacy
        15. Retail Pharmacy
        16. Online Pharmacy
      6. Saudi Arabia
        1. DNA Polymerase Inhibitors
        2. Reverse Transcriptase Inhibitors
        3. Protease Inhibitors
        4. Neuraminidase Inhibitors
        5. RNAi Antisense Therapeutics
        6. Capsid Inhibitors
        7. Others
        8. HIV
        9. Hepatitis
        10. Herpes
        11. Influenza
        12. Respiratory Syncytial Virus
        13. Others
        14. Hospital Pharmacy
        15. Retail Pharmacy
        16. Online Pharmacy
      7. South Africa
        1. DNA Polymerase Inhibitors
        2. Reverse Transcriptase Inhibitors
        3. Protease Inhibitors
        4. Neuraminidase Inhibitors
        5. RNAi Antisense Therapeutics
        6. Capsid Inhibitors
        7. Others
        8. HIV
        9. Hepatitis
        10. Herpes
        11. Influenza
        12. Respiratory Syncytial Virus
        13. Others
        14. Hospital Pharmacy
        15. Retail Pharmacy
        16. Online Pharmacy
      8. Egypt
        1. DNA Polymerase Inhibitors
        2. Reverse Transcriptase Inhibitors
        3. Protease Inhibitors
        4. Neuraminidase Inhibitors
        5. RNAi Antisense Therapeutics
        6. Capsid Inhibitors
        7. Others
        8. HIV
        9. Hepatitis
        10. Herpes
        11. Influenza
        12. Respiratory Syncytial Virus
        13. Others
        14. Hospital Pharmacy
        15. Retail Pharmacy
        16. Online Pharmacy
      9. Nigeria
        1. DNA Polymerase Inhibitors
        2. Reverse Transcriptase Inhibitors
        3. Protease Inhibitors
        4. Neuraminidase Inhibitors
        5. RNAi Antisense Therapeutics
        6. Capsid Inhibitors
        7. Others
        8. HIV
        9. Hepatitis
        10. Herpes
        11. Influenza
        12. Respiratory Syncytial Virus
        13. Others
        14. Hospital Pharmacy
        15. Retail Pharmacy
        16. Online Pharmacy
      10. Rest of MEA
        1. DNA Polymerase Inhibitors
        2. Reverse Transcriptase Inhibitors
        3. Protease Inhibitors
        4. Neuraminidase Inhibitors
        5. RNAi Antisense Therapeutics
        6. Capsid Inhibitors
        7. Others
        8. HIV
        9. Hepatitis
        10. Herpes
        11. Influenza
        12. Respiratory Syncytial Virus
        13. Others
        14. Hospital Pharmacy
        15. Retail Pharmacy
        16. Online Pharmacy
    5. LATAM
      1. LATAM Antiviral Drugs Market By Drug Class 2022-2034 (USD MILLION/ Units)
        1. DNA Polymerase Inhibitors
        2. Reverse Transcriptase Inhibitors
        3. Protease Inhibitors
        4. Neuraminidase Inhibitors
        5. RNAi Antisense Therapeutics
        6. Capsid Inhibitors
        7. Others
      2. LATAM Antiviral Drugs Market By Application 2022-2034 (USD MILLION/ Units)
        1. HIV
        2. Hepatitis
        3. Herpes
        4. Influenza
        5. Respiratory Syncytial Virus
        6. Others
      3. LATAM Antiviral Drugs Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacy
        2. Retail Pharmacy
        3. Online Pharmacy
      4. Brazil
        1. DNA Polymerase Inhibitors
        2. Reverse Transcriptase Inhibitors
        3. Protease Inhibitors
        4. Neuraminidase Inhibitors
        5. RNAi Antisense Therapeutics
        6. Capsid Inhibitors
        7. Others
        8. HIV
        9. Hepatitis
        10. Herpes
        11. Influenza
        12. Respiratory Syncytial Virus
        13. Others
        14. Hospital Pharmacy
        15. Retail Pharmacy
        16. Online Pharmacy
      5. Mexico
        1. DNA Polymerase Inhibitors
        2. Reverse Transcriptase Inhibitors
        3. Protease Inhibitors
        4. Neuraminidase Inhibitors
        5. RNAi Antisense Therapeutics
        6. Capsid Inhibitors
        7. Others
        8. HIV
        9. Hepatitis
        10. Herpes
        11. Influenza
        12. Respiratory Syncytial Virus
        13. Others
        14. Hospital Pharmacy
        15. Retail Pharmacy
        16. Online Pharmacy
      6. Argentina
        1. DNA Polymerase Inhibitors
        2. Reverse Transcriptase Inhibitors
        3. Protease Inhibitors
        4. Neuraminidase Inhibitors
        5. RNAi Antisense Therapeutics
        6. Capsid Inhibitors
        7. Others
        8. HIV
        9. Hepatitis
        10. Herpes
        11. Influenza
        12. Respiratory Syncytial Virus
        13. Others
        14. Hospital Pharmacy
        15. Retail Pharmacy
        16. Online Pharmacy
      7. Chile
        1. DNA Polymerase Inhibitors
        2. Reverse Transcriptase Inhibitors
        3. Protease Inhibitors
        4. Neuraminidase Inhibitors
        5. RNAi Antisense Therapeutics
        6. Capsid Inhibitors
        7. Others
        8. HIV
        9. Hepatitis
        10. Herpes
        11. Influenza
        12. Respiratory Syncytial Virus
        13. Others
        14. Hospital Pharmacy
        15. Retail Pharmacy
        16. Online Pharmacy
      8. Colombia
        1. DNA Polymerase Inhibitors
        2. Reverse Transcriptase Inhibitors
        3. Protease Inhibitors
        4. Neuraminidase Inhibitors
        5. RNAi Antisense Therapeutics
        6. Capsid Inhibitors
        7. Others
        8. HIV
        9. Hepatitis
        10. Herpes
        11. Influenza
        12. Respiratory Syncytial Virus
        13. Others
        14. Hospital Pharmacy
        15. Retail Pharmacy
        16. Online Pharmacy
      9. Rest of LATAM
        1. DNA Polymerase Inhibitors
        2. Reverse Transcriptase Inhibitors
        3. Protease Inhibitors
        4. Neuraminidase Inhibitors
        5. RNAi Antisense Therapeutics
        6. Capsid Inhibitors
        7. Others
        8. HIV
        9. Hepatitis
        10. Herpes
        11. Influenza
        12. Respiratory Syncytial Virus
        13. Others
        14. Hospital Pharmacy
        15. Retail Pharmacy
        16. Online Pharmacy
Report Details
−
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.